Precision medicine: from pharmacogenomics to pharmacoproteomics

被引：26

作者：

Chambliss, Allison B. ^{[1
,2
]}

Chan, Daniel W. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA

[2] USC, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA

来源：

CLINICAL PROTEOMICS | 2016年 / 13卷

关键词：

Pharmacogenomics; Proteomics; Biomarker; Precision medicine; GENOME-WIDE ASSOCIATION; HUMAN CELL-LINE; LUNG-CANCER PATIENTS; MASS-SPECTROMETRY; BREAST-CANCER; PERSONALIZED MEDICINE; CHEMICAL PROTEOMICS; DNA METHYLATION; DRUG DISCOVERY; RNA-SEQ;

D O I：

10.1186/s12014-016-9127-8

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.

引用

页数：9

共 79 条

[1] Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma [J].

Addona, Terri A. ;

Abbatiello, Susan E. ;

Schilling, Birgit ;

Skates, Steven J. ;

Mani, D. R. ;

Bunk, David M. ;

Spiegelman, Clifford H. ;

Zimmerman, Lisa J. ;

Ham, Amy-Joan L. ;

Keshishian, Hasmik ;

Hall, Steven C. ;

Allen, Simon ;

Blackman, Ronald K. ;

Borchers, Christoph H. ;

Buck, Charles ;

Cardasis, Helene L. ;

Cusack, Michael P. ;

Dodder, Nathan G. ;

Gibson, Bradford W. ;

Held, Jason M. ;

Hiltke, Tara ;

Jackson, Angela ;

Johansen, Eric B. ;

Kinsinger, Christopher R. ;

Li, Jing ;

Mesri, Mehdi ;

Neubert, Thomas A. ;

Niles, Richard K. ;

Pulsipher, Trenton C. ;

Ransohoff, David ;

Rodriguez, Henry ;

Rudnick, Paul A. ;

Smith, Derek ;

Tabb, David L. ;

Tegeler, Tony J. ;

Variyath, Asokan M. ;

Vega-Montoto, Lorenzo J. ;

Wahlander, Asa ;

Waldemarson, Sofia ;

Wang, Mu ;

Whiteaker, Jeffrey R. ;

Zhao, Lei ;

Anderson, N. Leigh ;

Fisher, Susan J. ;

Liebler, Daniel C. ;

Paulovich, Amanda G. ;

Regnier, Fred E. ;

Tempst, Paul ;

Carr, Steven A. .

NATURE BIOTECHNOLOGY, 2009, 27 (07) :633-U85

[2]

Aslibekyan S, 2013, EXPERT REV CARDIOVAS, V11, P355, DOI [10.1586/erc.12.134, 10.1586/ERC.12.134]

[3] The quantitative proteome of a human cell line [J].

Beck, Martin ;

Schmidt, Alexander ;

Malmstroem, Johan ;

Claassen, Manfred ;

Ori, Alessandro ;

Szymborska, Anna ;

Herzog, Franz ;

Rinner, Oliver ;

Ellenberg, Jan ;

Aebersold, Ruedi .

MOLECULAR SYSTEMS BIOLOGY, 2011, 7

[4] Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer [J].

Brauch, Hiltrud ;

Schwab, Matthias .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (04) :695-703

[5] Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy [J].

Cao, S. ;

Wang, S. ;

Ma, H. ;

Tang, S. ;

Sun, C. ;

Dai, J. ;

Wang, C. ;

Shu, Y. ;

Xu, L. ;

Yin, R. ;

Song, X. ;

Chen, H. ;

Han, B. ;

Li, Q. ;

Wu, J. ;

Bai, C. ;

Chen, J. ;

Jin, G. ;

Hu, Z. ;

Lu, D. ;

Shen, H. .

PHARMACOGENOMICS JOURNAL, 2016, 16 (01) :41-46

[6] Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer [J].

Chapal, N ;

Molina, L ;

Molina, F ;

Laplanche, M ;

Pau, B ;

Petit, P .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (04) :413-422

[7] A New Initiative on Precision Medicine [J].

Collins, Francis S. ;

Varmus, Harold .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (09) :793-795

[8] Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810 [J].

Colzani, Mara ;

Noberini, Roberta ;

Romanenghi, Mauro ;

Colella, Gennaro ;

Pasi, Maurizio ;

Fancelli, Daniele ;

Varasi, Mario ;

Minucci, Saverio ;

Bonaldi, Tiziana .

MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (06) :1495-1509

[9] UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan [J].

Cote, Jean-Francois ;

Kirzin, Sylvain ;

Krarnar, Andrew ;

Mosnier, Jean-Francois ;

Diebold, Marie-Daniele ;

Soubeyran, Isabelle ;

Thirouard, Anne-Sophie ;

Selves, Janick ;

Laurent-Puig, Pierre ;

Ychou, Marc .

CLINICAL CANCER RESEARCH, 2007, 13 (11) :3269-3275

[10] Moving towards individualized medicine with pharmacogenomics [J].

Evans, WE ;

Relling, MV .

NATURE, 2004, 429 (6990) :464-468

← 1 2 3 4 5 6 7 8 →